Maze Therapeutics Quarterly Cash Flow Statement
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
27.11+1.23 (+4.75%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maze Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Maze Therapeutics generated -$15.1 million of operating cash flow and spent $107,000 on capital expenditures. That left free cash flow of -$15.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Maze Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -44.73M | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M | -29.58M | -24.75M | 139.06M | -32.49M |
| Net Income growth (YoY) | — | — | — | — | -124.22% | — | — | — | — | — |
| Depreciation & Amortization | 391.00K | 444.00K | 499.00K | 571.00K | 649.00K | 684.00K | 705.00K | 788.00K | 854.00K | 950.00K |
| Stock-Based Compensation | 9.19M | 7.11M | 6.07M | 3.86M | 3.24M | 3.23M | 2.85M | 2.34M | 2.14M | 2.31M |
| Change in Working Capital | -1.60M | -18.39M | 1.00M | 2.08M | 1.05M | -146.00K | 2.33M | -4.50M | 3.64M | -166.00K |
| Operating Cash Flow | -15.05M | -39.11M | -27.73M | -24.64M | -30.05M | -29.52M | -22.45M | -23.20M | 145.05M | -23.44M |
| Capital Expenditures | -107.00K | -93.00K | -34.00K | -68.00K | -393.00K | -299.00K | -605.00K | -103.00K | -160.00K | -279.00K |
| Investing Cash Flow | -128.51M | 6.28M | -103.39M | -66.88M | -393.00K | -299.00K | -605.00K | -103.00K | -160.00K | -279.00K |
| Debt Issued | 0 | 39.40M | — | — | — | — | — | — | — | — |
| Financing Cash Flow | 147.44M | 42.36M | 3.59M | 143.76M | 612.00K | 127.38M | 70.26M | -2.15M | 154.00K | 24.58M |
| Net Change in Cash | 3.88M | 9.52M | -127.53M | 52.23M | -29.83M | 97.56M | 47.20M | -25.46M | 145.04M | 865.00K |
| Free Cash Flow | -15.16M | -39.21M | -27.76M | -24.71M | -30.45M | -29.82M | -23.06M | -23.31M | 144.89M | -23.72M |
This table shows 10 quarterly periods of Maze Therapeutics's cash flow statement, from Q2 2026 back to Q1 2024, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MAZE's reporting calendar. What is a cash flow statement?